A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Completed · Phase 3 · NCT02435433
Conditions: Hepatocellular Carcinoma
At a glance
- Research payments reported, 2025
- $38,269
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 399
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Ramucirumab (drug), Placebo (drug)
- Dates
- Started 2015-07-20; completion 2021-11-19
- Results posted
- Yes
The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be randomized to ramucirumab or placebo in a 2:1 ratio (Main Global Cohort and China Maximized Extended Enrollment \[MEE\] Cohort). Participants may also receive ramucirumab if eligible to be enrolled in Open-Label Expansion (OLE) Cohort.
From ClinicalTrials.gov, last updated 2023-01-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $38,269 in research payments for this study in 2025 (1 payments).
Products named: Cyramza
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Pres and Dir Georgetown College for Grgtwn Univ $38,269
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.